Althea Technologies Appoints Dr. Catherine J. Mackey to the Board of Directors

Share Article

Dr. Catherine J. Mackey has been appointed to the Board of Directors at Althea Technologies, a contract development and manufacturing organization for the pharmaceutical and biotechnology industries. Dr. Mackey's distinguished career in pharmaceutical R&D brings a wealth of experience and industry direction to the board at the San Diego-based service provider.

Althea Technologies, Inc.

Althea Technologies, Inc., a leading provider of contract development and manufacturing services for biopharmaceutical and parenteral products, announced today that Catherine J. Mackey, Ph.D., has been appointed to Althea’s Board of Directors. Dr. Mackey brings 28 years of experience in the biotechnology and pharmaceutical industries to the role. Most recently serving as Senior Vice President, Pfizer Worldwide Research & Development, and Site Director of Pfizer La Jolla Laboratories, Dr. Mackey was instrumental in creating San Diego’s largest pharmaceutical R&D center. She combined the ‘best of both’ large pharma and small biotech, resulting in a highly successful R&D organization that has delivered key oncology late stage and commercial drugs.

"Althea Technologies is very fortunate to have an industry veteran such as Dr. Catherine Mackey join our Board of Directors,” said Dr. Magda Marquet, Founder and Co-Chair of Althea Technologies. She added, “Dr. Mackey's extensive experience and outstanding achievements at Pfizer, DEKALB and Monsanto will immediately add an exciting dimension to both our board of directors and management teams."

“Over three decades, Dr. Mackey has proven herself to be both a visionary and a leader in the life science industry, and the entire Althea organization welcomes her to the team,” said Matt Mackowski, Co-Chair of Althea Technologies and Chairman of Telegraph Hill Partners. “Her addition to our board validates the great advancement in capabilities and technologies Althea has achieved over the past several years.”

On her appointment, Dr. Mackey commented, “As pharmaceutical companies continue to externalize R&D and manufacturing, the demand for high quality, innovative partners such as Althea will grow dramatically. I look forward to working with the Althea Board and management team to make Althea THE partner of choice for the industry.”

During her tenure at Pfizer, Dr. Mackey’s previous positions included Vice President of Strategic Alliances, and Group Director of Genomic and Proteomic Science. Before Pfizer, she was Vice President of Research at DEKALB, serving on the executive team that sold the company to Monsanto in 1998. Dr. Mackey is also very active in the local community. She serves as vice chair of CONNECT and on several nonprofit boards including BIOCOM, Rady Children’s Hospital, and Project Concern International.

Althea Technologies’ current Board of Directors consists of co-chairs, Magda Marquet and Matthew Mackowski, as well as Francois Ferre, Deval Lashkari and James Glavin.

About Althea Technologies, Inc.

Althea Technologies is a fully integrated, contract development and manufacturing organization that provides services for plasmid DNA, recombinant proteins, and sterile products. Located in San Diego, CA, Althea offers cell banking, process development, cGMP protein & plasmid production, analytical development, formulation and lyophilization development, and aseptic filling in vials & prefilled syringes for clinical development and commercialization. Althea’s formulation technology platform employs crystalomics that can be applied to a variety of peptides and proteins for high concentration or sustained release formulations. For more information, visit

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Lange
Visit website